OncoMatch/Clinical Trials/NCT06624475
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Is NCT06624475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Relatlimab plus Nivolumab for basal cell carcinoma.
Treatment: Nivolumab · Relatlimab plus Nivolumab — This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Is currently receiving any other investigational agents.
Cannot have received: investigational product/device
Has participated in a study of an investigational product and received study treatment or used an investigational device within 4 weeks of the first dose of study treatment.
Cannot have received: radiation therapy
Exception: Participants must have recovered (i.e., Grade ≤1 or at baseline) from radiation related toxicities prior to first study treatment.
Radiation therapy within 2 weeks prior to first study treatment.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/microliter; Platelets ≥ 100,000/microliter
Kidney function
Creatinine clearance > 30 mL/min (Cockcroft Gault formula)
Liver function
Total bilirubin >1.5 x institutional upper limit of normal (except Gilbert Syndrome <3.0xULN); AST ≤ 3 x ULN; ALT ≤ 3 x ULN
Adequate bone marrow function: Absolute neutrophil count ≥ 1,500/microliter; Platelets ≥ 100,000/microliter. Adequate hepatic function: Total bilirubin >1.5 x institutional upper limit of normal (except participants with Gilbert Syndrome who must have a total bilirubin level of <3.0xULN); AST ≤ 3 x institutional upper limit of normal; ALT ≤ 3 x institutional upper limit of normal. Adequate renal function: Creatinine clearance > 30 mL/min (using the Cockcroft Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine · Irvine, California
- University of California, San Diego Moores Cancer Center · La Jolla, California
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify